In the final experiment, we assessed whether intrahippocampal rimonabant administration would attenuate non-mnemonic effects produced by cannabinoids, as assessed in the tetrad assay. As previously reported (Compton, et al 1992), CP-55,940 (0.15 mg/kg, i.p.) produced locomotor suppressive (F (2,16) = 121, p < 0.001; Figure 5A), analgesic (F (2,16) = 6.1, p < 0.05; Figure 5B), cataleptic (Figure 5C), and hypothermic (F (2,16) = 42, p < 0.001; Figure 5D) effects. Intrahippocampal rimonabant (0.06 μg) administration failed to attenuate any of these effects, as indicated by post hoc analyses.
